Five-Year Results From a Scandinavian Sarcoma Group Study (SSG XIII) of Adjuvant Chemotherapy Combined With Accelerated Radiotherapy in High-Risk Soft Tissue Sarcoma of Extremities and Trunk Wall

Journal Article · Thu Dec 01 04:00:00 EST 2011 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2010.07.037· OSTI ID:22054489

Jebsen, Nina L ^[1]; Bruland, Oyvind S ^[2]; Eriksson, Mikael; Engellau, Jacob ^[3]; Turesson, Ingela ^[4]; Folin, Annika ^[5]; Trovik, Clement S ^[6]; Hall, Kirsten Sundby ^[7]

---

1. Department of Surgical Sciences, University of Bergen Faculty of Medicine, Bergen, Norway and Department of Oncology, Haukeland University Hospital, Bergen (Norway)
2. Cancer Clinic, Norwegian Radium Hospital, Oslo University Hospital and University of Oslo Faculty Division, Clinical Medicine, Oslo (Norway)
3. Department of Oncology, Skane University Hospital, Lund (Sweden)
4. Department of Oncology, Uppsala University Hospital, Uppsala (Sweden)
5. Department of Oncology, Karolinska Hospital, Stockholm (Sweden)
6. Departments of Oncology and of Orthopedics, Haukeland University Hospital, Bergen (Norway)
7. Cancer Clinic, Norwegian Radium Hospital, Oslo University Hospital, Oslo (Norway)

Purpose: To evaluate adjuvant chemotherapy and interpolated accelerated radiotherapy (RT) for adult patients with high-risk soft tissue sarcoma in the extremities or trunk wall. Methods and Materials: High-risk soft tissue sarcoma was defined as high-grade malignancy and at least two of the following criteria: size {>=}8 cm, vascular invasion, or necrosis. Six cycles of doxorubicin and ifosfamide were prescribed for all patients. RT to a total dose of 36 Gy (1.8 Gy twice daily) was inserted between two chemotherapy cycles after marginal margin resection regardless of tumor depth or after wide-margin resection for deep-seated tumors. RT was boosted to 45 Gy in a split-course design in the case of intralesional margin resection. Results: A total of 119 patients were eligible, with a median follow-up of 5 years. The 5-year estimate of the local recurrence, metastasis-free survival, and overall survival rate was 12%, 59%, and 68%, respectively. The group receiving RT to 36 Gy had a local recurrence rate of 10%. In contrast, the local recurrence rate was 29% in the group treated with RT to 45 Gy. The presence of vascular invasion and low chemotherapy dose intensity had a negative effect on metastasis-free and overall survival. Toxicity was moderate after both the chemotherapy and the RT. Conclusions: Accelerated RT interposed between chemotherapy cycles in a selected population of patients with high-risk soft tissue sarcoma resulted in good local and distant disease control, with acceptable treatment-related morbidity. The greater radiation dose administered after intralesional surgery was not sufficient to compensate for the poorer surgical margin. Vascular invasion was the most important prognostic factor for metastasis-free and overall survival.

• OSTI ID: 22054489
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 81; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ADULTS
CHEMOTHERAPY
DEPTH
DISEASE INCIDENCE
DOXORUBICIN
HAZARDS
METASTASES
NECROSIS
PATIENTS
RADIATION DOSES
RADIOTHERAPY
SARCOMAS
SURGERY
TOXICITY